Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesHarrow Health Inc

Harrow Health Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
30.895 USD 3.42 ( 12.47%)
Last update at 2026-11-10T14:51:00Z
VOLUME
583839
Market Cap
656.69M

Momentum Score

…

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
28.91
Low
33.68
High
52 Week Price Range
7.60
Low
22.63
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Harrow Health is a NASDAQ-listed healthcare company focused on eye care, operating ophthalmic commercial businesses and pharmacy services that distribute specialty prescription products. Long-term growth may be supported by an aging population with rising eye disease prevalence, expansion of prescription and services revenue, and inorganic growth from product launches and acquisitions.

Principal risks include regulatory and reimbursement pressure, competition from larger pharmaceutical and generic manufacturers, execution risk around commercialization and acquisition integration, and revenue concentration.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
27.47
Dividend Yield
-
Revenue TTM
138.68M
Revenue Per Share
4.09
Gross Profit TTM
63.21M
Debt / Equity
2.71
ROE
-76.67%
Net Debt
116.42M
ROCE
-0.67%
Diluted EPS TTM
-0.94

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.01M -17.87M -3.42M -0.12M 14.62M
Minority interest - 0.00M -0.06M 0.29M -0.29M
Net income -14.09M -18.01M -3.42M -2.59M 14.62M
Selling general administrative 58.24M 41.31M 0.03M 33.10M 29.24M
Selling and marketing expenses - - 31.22M - -
Gross profit 63.21M 54.26M 34.41M 34.42M 24.85M
Reconciled depreciation 3.67M 2.40M 2.74M 2.66M 1.84M
Ebit -1.75M -0.28M -1.63M -0.50M -4.82M
Ebitda 1.92M 2.11M 1.11M 2.16M -2.98M
Depreciation and amortization 3.67M 2.40M 2.74M 2.66M 1.84M
Non operating income net other -8.69M -14.05M -0.07M 7.18M 22.57M
Operating income -1.75M -0.28M -1.63M -0.50M -5.22M
Other operating expenses 86.68M 70.61M 48.12M 51.93M 46.59M
Interest expense 7.24M 5.44M 2.24M 2.50M 2.73M
Tax provision 0.07M 0.13M 0.00M 0.00M 0.00M
Interest income - - - 4.05M 20.13M
Net interest income -7.24M -5.44M -2.24M -2.50M -2.73M
Non recurring - 0.25M 0.36M 4.04M -
Income tax expense 0.07M 0.13M 0.00M 2.47M -19.45M
Total revenue 88.59M 72.48M 48.87M 51.16M 41.37M
Total operating expenses 61.29M 52.40M 33.66M 35.18M 30.07M
Cost of revenue 25.38M 18.21M 14.46M 16.75M 16.52M
Total other income expense net -12.27M -17.59M -1.78M 0.38M 22.57M
Net income from continuing ops -14.09M -18.01M -3.42M -0.12M 14.62M
Net income applicable to common shares -14.09M -18.48M -3.36M 0.17M 14.62M
Preferred stock and other adjustments - 0.47M - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 311.75M 157.02M 98.33M 57.47M 59.09M
Intangible assets 162.04M 25.84M 17.13M 1.94M 2.34M
Other current assets 8.95M 21.99M 1.26M 0.95M 0.79M
Total liab 241.75M 130.14M 87.40M 30.65M 31.67M
Total stockholder equity 70.36M 27.24M 11.29M 27.18M 27.71M
Deferred long term liab - 1.95M - - -
Other current liab 27.04M -0.84M 4.25M 2.31M 2.41M
Common stock 0.04M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.04M 0.03M 0.03M 0.03M 0.03M
Retained earnings -133.90M -109.49M -95.41M -77.40M -74.04M
Other liab - - - 0.80M 0.80M
Good will 0.33M 0.33M 0.33M 0.33M 0.33M
Other assets - 1.59M - 0.01M -
Cash 74.08M 96.27M 42.17M 4.10M 4.75M
Total current liabilities 49.34M 18.63M 9.72M 10.80M 12.28M
Current deferred revenue 0.07M 0.11M 0.02M 0.07M 0.06M
Net debt 116.42M 7.90M 35.79M 19.43M 16.24M
Short term debt 0.81M 0.72M 0.28M 4.49M 2.41M
Short long term debt - - - 3.90M 1.77M
Short long term debt total 190.50M 104.17M 77.96M 23.53M 20.99M
Other stockholder equity 204.63M 136.70M 106.67M 104.56M 101.73M
Property plant equipment - 3.49M 3.14M 4.45M 5.38M
Total current assets 139.07M 118.26M 60.66M 40.13M 36.77M
Long term investments - 0.00M 11.13M 3.82M 7.71M
Net tangible assets - 1.43M -6.17M 24.91M 25.04M
Short term investments 8.68M 5.59M 8.50M 28.45M 25.20M
Net receivables 36.49M 6.39M 4.52M 2.66M 2.73M
Long term debt 183.17M 104.17M 71.65M 12.38M 12.22M
Inventory 10.87M 6.54M 4.22M 3.96M 3.30M
Accounts payable 21.42M 18.63M 5.17M 3.93M 7.41M
Noncontrolling interest in consolidated entity - -0.35M -0.35M -0.35M -0.29M
Accumulated other comprehensive income -0.41M - - - -5.39M
Common stock total equity - 0.03M 0.03M 0.03M 0.03M
Retained earnings total equity - -109.49M -95.41M -77.40M -74.04M
Non currrent assets other -2.14M 1.95M 12.45M 3.82M 7.71M
Non current assets total 172.68M 37.17M 37.67M 17.34M 22.32M
Capital lease obligations 7.33M 8.05M 6.30M 7.26M 7.00M
Long term debt total - 104.17M 71.65M 12.38M 12.22M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.74M -2.77M -0.98M -1.83M 0.00M
Change to liabilities 2.77M 2.50M -4.46M 1.18M 3.44M
Total cashflows from investing activities -1.74M -18.69M -0.98M -1.83M -2.20M
Net borrowings 31.72M 55.11M 1.47M -0.75M -0.74M
Total cash from financing activities 54.14M 51.47M 1.43M -1.01M 4.13M
Change to operating activities - 0.15M -0.10M -0.64M 0.95M
Net income -14.09M -18.01M -3.42M -0.12M 14.62M
Change in cash 54.10M 37.87M -0.65M -1.89M 2.62M
Begin period cash flow 42.17M 4.30M 4.95M 6.84M 4.22M
End period cash flow 96.27M 42.17M 4.30M 4.95M 6.84M
Total cash from operating activities 1.71M 5.08M -1.10M 0.95M 0.69M
Issuance of capital stock 22.66M 10.65M - 0.00M 0.64M
Depreciation 3.67M 2.40M 2.74M 2.66M 1.84M
Other cashflows from investing activities 0.85M -14.13M -0.12M -0.36M -0.43M
Dividends paid 0.00M 0.13M 0.13M 0.13M 0.13M
Change to inventory -2.32M -0.26M -0.66M -2.27M 0.41M
Change to account receivables -1.86M -1.83M -0.87M -0.10M -0.38M
Sale purchase of stock 23.30M -11.00M - 0.77M 4.88M
Other cashflows from financing activities 31.50M -19.19M 2.94M 0.49M 4.18M
Change to netincome 10.97M 6.49M 3.53M -0.38M -19.83M
Capital expenditures 7.77M 28.51M 0.99M 1.84M 2.20M
Change receivables -1.86M -1.83M -0.87M -0.10M -0.38M
Cash flows other operating 2.39M 13.79M 2.43M -0.01M -0.03M
Cash and cash equivalents changes 54.10M 37.87M -0.65M -1.89M 2.62M
Change in working capital -5.57M -0.25M -6.27M -1.72M 3.44M
Stock based compensation 7.97M 5.75M 2.86M 2.02M 2.64M
Other non cash items 9.72M 0.68M 0.81M 0.51M 0.61M
Free cash flow -6.07M -23.43M -2.09M -0.89M -1.52M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HROW
Harrow Health Inc		 3.42
12.47%		 30.89 - - 3.44 6.33 4.27 55.80
MKKGY
Merck KGaA ADR		 -0.14
0.42%		 33.57 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 0.40
0.24%		 170.10 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.31
1.47%		 20.78 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 42.77 - 10.66 0.01 1.16 2.94 23.11

Profile*

Harrow Health Inc

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

102 Woodmont Boulevard, Nashville, TN, United States, 37205

615 733 4730

https://www.harrow.com

315

Name Title Year Born
Mr. Mark L. Baum J.D. CEO & Chairman 1973
Mr. Andrew R. Boll C.F.A., C.M.A., CFA, CMA CFO & Corp. Sec. 1982
Dr. Robert J. Kammer D.D.S. Special Advisor 1949
Mr. John P. Saharek MBA Chief Commercial Officer 1960
Mr. David Moufarrège VP of Technology NA
Jamie Webb Director of Communications & Investor Relations NA
Dr. Dennis E Saadeh Pharm.D. Chief of Formulation Strategy NA
Dr. Larry M. Dillaha M.D. Chief Medical Officer 1963
Mr. Andrew Livingston Chief Innovation Officer NA
Ms. Kim Barratt Chief Talent Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…